Wepresent a case of a suspected myocarditis and multiorganic toxicity due to
immune checkpoint inhibitors used in cancer treatment. Some cases have been
reported in the literature although the peculiarity of this one was the
multiorganic and simultaneously affectation. We are attending the striking
development of cancer treatment, which allows patients in the most astonishing
cases to the complete resolution of the disease. However, to get the aim many
trials and surveillance studies must been performance. The release of
biological targeted medications has passed over the feared chemo resistance to
conventional drugs. But we need to balance even though the prognosis is often
very poor, a detailed assessment of the advantages and disadvantages taking
into account the patient and family’s preferences.
Howeverwe could think that more specific treatment would lead us to less aggressive
adverse events, but that’s not the case with immune checkpoint inhibition
drugs. A 78-year-old male, ex-smoker, who had a history of ischemic heart
disease 10 years ago, with preserved ejection fraction, was diagnosed in June,
2016 of a non-small cell lung cancer (squamous cell carcinoma disseminated to
liver without any remarkable molecular profiling). He was proposed to take part
in a clinical essay that evaluate the answer to nivolumab 3mg/kg every 2 weeks
associated to ipilimumab 1 mg/kg every 6 weeks; beginning the above mentioned
treatment five months later and receiving the first dose of nivolumab on
November 24th.
No comments:
Post a Comment